Creative Medical shares surge 10.73% intraday after positive interim ADAPT trial data for CELZ-201 in chronic lower back pain, marking a major clinical inflection point.

Creative Medical Technology Holdings (NASDAQ: CELZ) surged 10.73% intraday after announcing positive interim 180-day data from its ADAPT trial for CELZ-201 (Olastrocel), a cell therapy targeting chronic lower back pain. The results showed statistically significant improvements in functional disability (−15.3-point ODI% reduction, p=0.0003) and pain (−3.9-point reduction on a 10-point scale, p<0.00005), with 79% of patients achieving clinically meaningful outcomes. An independent Data Safety Monitoring Board confirmed no serious adverse events, reinforcing the therapy’s safety profile. The company emphasized this milestone as a transition from a clinical program to a strategic asset, with plans for regulatory engagement and commercialization. The data addresses a $multi-billion-dollar market gap for non-surgical, disease-modifying back pain solutions, positioning CELZ-201 as a potential disruptive therapy.